Showing results (451-460 of 554) with videos related to
Sort By:
Pageof 56
Pigment Cell & Melanoma Research|January 10, 2020
Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directionsIsabella C Glitza, Keiran S M Smalley, Priscilla K Brastianos, et al.The Lancet. Oncology|December 7, 2020
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trialThomas Powles, Elizabeth R Plimack, Denis Soulières, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2024
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinomaN Agarwal, J Brugarolas, P Ghatalia, et al.Journal of Pain and Symptom Management|January 2, 2025
Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical TrialsSarah N Price, Ju-Whei Lee, Ilana F Gareen, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 23, 2013
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) studyUday B Dandamudi, Musie Ghebremichael, Jeffrey A Sosman, et al.Cancer|March 23, 2023
The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective studyShaked Lev-Ari, Michael Serzan, Tianmin Wu, et al.Cancer|April 30, 2009
Innovations and challenges in renal cancer: summary statement from the Third Cambridge ConferenceMichael B Atkins, Ronald M Bukowski, Bernard J Escudier, et al.Journal for Immunotherapy of Cancer|December 21, 2019
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)Brian I Rini, Dena Battle, Robert A Figlin, et al.BJU International|April 2, 2020
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinomaSumanta K Pal, David F McDermott, Michael B Atkins, et al.Cancer|April 6, 2019
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinomaMartin H Voss, Rupal S Bhatt, Nicholas J Vogelzang, et al.Pageof 56